Sonoma pharmaceuticals reports second fiscal quarter 2025 financial results

Revenue increased 31% for the quarter compared to same period prior year positive cash flows from operations of $0.35 million for the quarter net loss improved 59% for the quarter compared to same period prior year net loss per share improved 90% for the quarter compared to same period prior year boulder, co / accesswire / november 7, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa),a global healthcare leader developing and producing patented microcyn® technology based stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced financial results for its second fiscal quarter ended september 30, 2024. "our results this quarter reflect the diligent efforts by sonoma's team to grow our business and drive toward profitability," said amy trombly, ceo of sonoma.
SNOA Ratings Summary
SNOA Quant Ranking